NCT02089295View on ClinicalTrials.gov

Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Healthy
Interventions
DRUG

Oxycodone

One capsule of 5 mg PF-00345439 Formulation K, single dose, under fed conditions

DRUG

Oxycodone

One capsule of 20 mg PF-00345439 Formulation K, single dose, under fed conditions

DRUG

Oxycodone

One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions

Trial Locations (2)

66211

Pfizer Investigational Site, Overland Park

66212

Pfizer Investigational Site, Overland Park

Sponsors

Lead Sponsor

Pain Therapeutics
All Listed Sponsors
lead

Pain Therapeutics

INDUSTRY

NCT02089295 - Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions | Biotech Hunter | Biotech Hunter